Floatz Rating
D30/100
Confidence
Indicative
Sponsor
RenJi Hospital
Modality
radiopharmaceutical
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07026110CT.gov Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pneumonitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [68ga]ga-nota-t4 (this asset) | RenJi Hospital | N/A | D · 30 |
| Amifostine | MedImmune LLC | P2 | B |
| Prednisone | ECOG-ACRIN Cancer Research Group | P2 | CCC |
| Human Immunoglobulins | ECOG-ACRIN Cancer Research Group | P2 | CCC |
| Infliximab | ECOG-ACRIN Cancer Research Group | P2 | CCC |
| Tocilizumab | National Cancer Institute (NCI) | P2 | CCC |
| Poly(Acetyl, Arginyl)Glucosamine (25000-50000 Mw) | Synspira, Inc. | P1 | CC |
| [18F]F-RESCA-T4 | RenJi Hospital | N/A | D |
| [18f]f-resca-rt4 | RenJi Hospital | N/A | D |
+3 more in the Pneumonitis cohort
Other indications for [68ga]ga-nota-t4
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Nasopharyngeal Carcinoma | — | P2/3 | B · 57 |
| Urothelial Carcinoma | — | P2/3 | B · 57 |
| Carcinoma | — | P2/3 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [68ga]ga-nota-t4 in Pneumonitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68gaga-nota-t4-pneumonitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →